(VIANEWS) – Bergenbio’s shares have increased by 11.45% on Oslo Bors Benchmark Index_GI.
Bergenbio’s stock (GI: BGBIO.OL) saw an 11.45% gain to kr0.12 at 15:44 EST on Monday, continuing its upward trajectory since last time. This rise was in line with overall market trends as well, as Oslo Bors Benchmark Index_GI had also experienced growth at 0.96% to 1,243.72 and continued rising.
Bergenbio’s last closing price was kr0.11, placing it 99.16% below its 52-week high of kr13.03; even after recently experiencing an uptick, this stock remains down 888.84% from its 52-week low of kr10.00.
Bergenbio’s stock price may have seen an upswing due to positive market sentiment or expectations regarding their financial performance, among other factors. Before making investment decisions based on stock price alone, however, it is imperative that investors consider all fundamental aspects of the company, such as its financial health and growth prospects.
About BERGENBIO
BerGenBio ASA is a clinical-stage biopharmaceutical company focused on creating innovative medicines to combat immune-evasive, drug-resistant, metastatic cancers as well as respiratory illnesses. Bemcentinib, the company’s lead product, is an oral once-daily inhibitor of AXL receptor tyrosine kinase currently in Phase 1b/2a clinical trials for non-small cell lung cancer, acute myeloid leukemia and COVID-19. Bemcentinib is being evaluated for use against glioblastoma, 2L lung cancer, melanoma, pancreatic cancer and mesothelioma. BerGenBio has also begun Phase 1b trials for an anti-AXL function-blocking monoclonal antibody called Tilvestamab to treat ovarian cancer, while mipasetamab uzoptirine will undergo Phase 1 trials against solid tumors. BerGenBio collaborated with Merck & Co for clinical trials before being established as a company in 2007 in Bergen, Norway.
Yearly Analysis
According to Bergenbio’s stock data, its share is currently trading at kr0.12, lower than its 52-week high of 13.00 but higher than its 52-week low of 0.08; this indicates a high level of volatility over the past year.
Bergenbio’s EBITDA stands at -2.91, which indicates it is operating at a loss and should be carefully evaluated by investors as this indicates it may not generate sufficient revenues to cover its expenses.
Overall, investors should proceed with caution when considering Bergenbio as an investment. Though its stock may appear undervalued relative to its 52-week high price point, negative EBITDA and historical volatility suggest there could be substantial risks involved with investing in Bergenbio – it’s essential to conduct more extensive research before making any definitive investment decisions.
Technical Analysis
BERGENBIO stock is trading at an approximate value of kr0.09, significantly below both its 50-day moving average of kr0.13 and 200-day moving average of kr4.18. This indicates that its stock has been trending down over recent months.
However, it should be noted that today’s trading volume of 74164120 was 136% greater than its average volume of 31425400 – suggesting an increased interest in the stock that could cause it to go up in price in short order.
In terms of volatility, BERGENBIO has experienced intraday variation averages for the last week, month, and quarter that averaged 5.57%, 0.37%, and 6.30% respectively; its highest average volatility amplitude during those timeframes reached 16.40% (week), 5.43% (month), and 6.30
Overall, while BERGENBIO’s stock is trading below its moving averages and experiencing some volatility, its increased trading volume may signal optimism among investors. However, it is essential to closely track its performance as well as any news or developments which could potentially alter its price.
Equity Analysis
Bergenbio currently boasts a negative trailing twelve months earnings per share (EPS) figure of kr-2.83, signalling to investors that it may not be producing profits for them. A negative EPS can serve as a warning signal that suggests the company may not be performing financially well.
Additionally, the return on equity (ROE) for the twelve trailing months stands at negative -179.58% – suggesting that profits are being generated inefficiently and shareholder equity not utilized efficiently by the business. A negative ROE could indicate financial distress or inefficiency within its operations.
Overall, these financial indicators suggest that Bergenbio may not represent an attractive investment opportunity at this time. Potential investors should conduct further investigation of its financial performance and management strategies before making their final investment decision.
More news about BERGENBIO (BGBIO.OL).
